Search Bar & Filters
Found 12 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the drug INCA033989 compared with the best available therapy in participants who have essential thrombocythemia ET with a CALR mutation and who have previously been treated with cytoreductive therapy. This phase 3, randomized, open-label study aims to assess the treatment effects in this specific group of patients with high-risk ET. Participants will receive either INCA033989 administered intravenously according to the study protocol or the best available therapy chosen by the investigator. The study treatments are given in parallel groups and will be monitored to compare responses and safety. The main study period includes treatment and observation up to at least 48 weeks, with follow-up for adverse events for 60 days after the last dose. During the study, participants will attend regular visits for assessments including clinical and hematologic responses, mutation frequency measurements, symptom assessments, and fatigue evaluations. Researchers will monitor treatment-emergent adverse events and measure durable responses at weeks 24 and 48. The total study duration extends until November 2030, with ongoing monitoring of patient health and responses throughout the treatment and follow-up periods.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of rilvegostomig combined with fluoropyrimidine and trastuzumab deruxtecan T-DXd compared to trastuzumab, chemotherapy, and pembrolizumab in participants with HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 combined positive score CPS of 1 or higher. This Phase 3, randomized, open-label study also includes a separate group receiving rilvegostomig with trastuzumab and chemotherapy to understand the contribution of each treatment component. The study is being conducted globally across many sites in about 25 countries. Participants are assigned to one of three treatment groups Arm A receives rilvegostomig, fluoropyrimidine capecitabine or 5-fluorouracil, and trastuzumab deruxtecan Arm B receives pembrolizumab, trastuzumab, and chemotherapy 5-fluorouracil plus cisplatin or capecitabine plus oxaliplatin Arm C receives rilvegostomig, trastuzumab, and chemotherapy. Treatments are administered mainly through intravenous infusions every three weeks, with capecitabine taken orally twice daily. The study aims to assess the role of each treatment combination over time. During the study, participants will undergo regular assessments including tumor measurements, safety checks for adverse events, and blood tests to monitor drug levels and immune responses. Researchers will track progression-free survival and overall survival for up to six years, along with response rates and treatment side effects. The study includes ongoing monitoring for eating difficulties and side-effect impact. Participants will be followed closely throughout treatment and for years afterward to evaluate long-term outcomes and safety.
Actively Recruiting
Researchers are studying an experimental drug called odronextamab combined with chemotherapy in patients with Diffuse Large B-cell Lymphoma DLBCL. This includes adults with untreated DLBCL as well as those whose disease has returned or not responded to treatment. The study aims to evaluate the safety, dosing, and effectiveness of odronextamab plus chemotherapy compared to the current standard treatment, rituximab combined with chemotherapy. The study is divided into Part 1A and 1B, which focus on determining safe doses and schedules of odronextamab combined with chemotherapy drugs including cyclophosphamide, doxorubicin, vincristine, and prednisone or prednisolone. Part 2 is a randomized comparison where participants receive either odronextamab plus chemotherapy or rituximab plus chemotherapy. Odronextamab and rituximab are given by intravenous infusion, with rituximab also possibly given subcutaneously. Participants will be monitored for side effects, disease progression, and quality of life over time. Assessments include measuring drug levels in the blood, immune response to the drug, and physical functioning questionnaires. The study will follow participants for up to five years to evaluate progression-free survival and other outcomes. Safety and adverse events will be tracked for up to two years.
Actively Recruiting
Researchers are evaluating an experimental drug called odronextamab combined with lenalidomide for adults with relapsed or refractory Follicular Lymphoma FL or Marginal Zone Lymphoma MZL, which are subtypes of Non-Hodgkins Lymphoma NHL. This Phase 3 study includes two parts Part 1 to assess safety and dosing of the combination, and Part 2 to compare its effectiveness and safety against the current standard treatment of rituximab plus lenalidomide. The combination of odronextamab and lenalidomide is a first-in-human treatment being explored in this trial. In Part 1, participants receive odronextamab with lenalidomide to evaluate safety and determine dosing. In Part 2, participants are randomly assigned to receive either odronextamab plus lenalidomide or rituximab plus lenalidomide followed by lenalidomide alone, allowing comparison between the new combination and standard care. Both treatment combinations are administered according to the study protocol. Participants will be monitored for side effects, treatment tolerability, and disease progression through scheduled assessments including imaging scans and laboratory tests. Researchers will measure drug levels in the blood, immune responses against odronextamab, and quality of life impacts using questionnaires. Safety monitoring continues for up to two years, while efficacy outcomes such as progression-free survival and response duration are followed for up to five years, with ongoing evaluations throughout the study period.
Actively Recruiting
Researchers are evaluating an experimental drug called odronextamab in adults with previously untreated follicular lymphoma, a type of non-Hodgkin lymphoma. The study consists of two parts Part 1 focuses on assessing the safety and tolerability of odronextamab alone, while Part 2 compares odronextamab to rituximab combined with chemotherapy, which is the current standard treatment. The research also explores side effects, drug levels in the blood, immune responses against the drug, and effects on quality of life and daily activities. Participants in Part 1 receive only odronextamab. In Part 2, participants are randomly assigned to one of two groups one group receives odronextamab followed by maintenance treatment with the same drug, and the other group receives rituximab combined with chemotherapy followed by rituximab maintenance. Chemotherapy options include combinations of cyclophosphamide, doxorubicin, vincristine, prednisone, and bendamustine, administered as described in the study protocol. Throughout the study, participants undergo regular assessments including imaging scans to measure disease, blood tests to monitor drug levels and immune response, and evaluations of physical function and quality of life. Researchers track adverse events and treatment responses up to five years. Safety and effectiveness are closely monitored, with key outcomes measured at intervals up to 30 months and beyond. The total participation time varies depending on treatment and follow-up schedules.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of combining gedatolisib with palbociclib and endocrine therapy compared to endocrine therapy with ribociclib for treating adults with locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer. This Phase 3, open-label, randomized clinical trial focuses on patients who are either endocrine-resistant or endocrine-sensitive based on their cancer progression and prior treatments. Participants will be assigned based on endocrine sensitivity status to one of two studies. Study 1 includes patients with endocrine-resistant cancer receiving either gedatolisib plus palbociclib and fulvestrant or ribociclib with fulvestrant. Study 2 includes endocrine-sensitive patients treated with gedatolisib plus palbociclib and letrozole or ribociclib plus letrozole. Gedatolisib is given intravenously once weekly for three weeks followed by a week off. Palbociclib and ribociclib are taken orally on days 1 to 21 of each 28-day cycle. Fulvestrant is administered by intramuscular injection every 2 to 4 weeks, while letrozole is taken orally daily. Throughout the study, participants undergo regular assessments including scans and laboratory tests to monitor disease progression and safety. Researchers measure outcomes such as progression-free survival, overall survival, response rates, duration and time to response, clinical benefits, quality of life, and adverse events over approximately 48 months. The trial includes screening to confirm eligibility and ongoing monitoring during and after treatment to evaluate the treatments effects and safety.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of trastuzumab deruxtecan T-DXd combined with rilvegostomig, and T-DXd alone, compared with the standard treatment of gemcitabine, cisplatin, and durvalumab for patients with advanced, untreated HER2-expressing biliary tract cancer. This Phase 3 study focuses on patients with locally advanced or metastatic disease, aiming to compare overall survival and other outcomes across different treatment groups. Participants are assigned to one of three groups one receiving T-DXd and rilvegostomig together, another receiving T-DXd alone, and a third receiving the standard care of gemcitabine, cisplatin, and durvalumab. All treatments are given by intravenous infusion. The study includes an initial safety run-in phase followed by a randomized portion where patients receive assigned treatments until disease progression or other criteria are met. The study is estimated to continue for up to 50 months after the first patient is randomized. During the trial, participants will have tumor samples collected, and their disease will be monitored through imaging and clinical assessments. Researchers will evaluate safety, tolerability, overall survival, progression-free survival, response rates, and patient-reported outcomes like side effects and physical functioning. Blood samples will be taken to study drug levels and immune responses. The study plans to follow participants for long-term outcomes and side effects, with regular visits scheduled throughout the study duration.
Actively Recruiting
Researchers are evaluating the safety of anumigilimab, a biological drug, in adults with sickle cell disease SCD. This phase 2a, global, multicenter, randomized, double-blind, placebo-controlled study aims to determine the maximum tolerated dose of anumigilimab when given subcutaneously and to monitor its safety over a long treatment period. The study involves participants with confirmed SCD who have experienced vaso-occlusive crises requiring medical treatment within the past year. Participants will be randomly assigned to receive either anumigilimab or a matching placebo. The treatment includes a 12-week dose escalation period where the dose is increased to each participants individual maximum tolerated dose based on safety and neutrophil counts, followed by a 52-week maintenance period at that dose. The placebo group will receive volume-matched saline injections subcutaneously. The study uses a quadruple-blind design to ensure unbiased evaluation. During the 64 weeks of treatment, participants will be closely monitored for adverse events, changes in laboratory assessments, vital signs, and immune responses. The primary outcomes focus on treatment-emergent adverse events, adverse events of special interest, and clinically relevant changes from baseline. Secondary outcomes include serum concentration of the drug and the annualized rate of vaso-occlusive crises during maintenance. The study lasts until 75 weeks from baseline, assessing safety and tolerability throughout.
Actively Recruiting
Researchers are evaluating the efficacy and safety of olverembatinib compared to bosutinib in patients with chronic phase chronic myeloid leukemia CML-CP. This phase 3 randomized study includes patients previously treated with at least two tyrosine kinase inhibitors TKIs and also examines olverembatinib in a single-arm group of CML-CP patients with the T315I mutation. The study addresses treatment options for patients with limited effective therapies and includes a crossover option for those meeting failure criteria while on bosutinib. Participants in Part A will be randomly assigned to receive either olverembatinib every other day or bosutinib once daily. Part B involves patients with the T315I mutation receiving olverembatinib alone. Treatment cycles are 28 days, with pharmacokinetic assessments after the first two cycles. Patients may continue treatment and be monitored for up to five years to evaluate long-term outcomes and safety. During the study, participants will undergo assessments including molecular response rates at 24 and 96 weeks, cytogenetic response evaluations at multiple intervals, and monitoring for adverse events. Researchers will also track progression-free and overall survival. Organ function and performance status will be regularly evaluated to ensure safety and treatment adherence throughout the study duration.
Actively Recruiting
Researchers are evaluating whether adding revumenib to standard intensive chemotherapy improves outcomes for participants newly diagnosed with acute myeloid leukemia AML who have a specific NPM1 genetic mutation. This Phase 3 study also assesses the safety of combining revumenib with chemotherapy compared to chemotherapy alone. Participants must be eligible for intensive chemotherapy and meet specific health and mutation criteria. Participants will be randomly assigned to one of two groups one group receives revumenib orally combined with an intensive chemotherapy regimen of cytarabine and daunorubicin given by intravenous infusion, while the other group receives a placebo orally with the same chemotherapy regimen. The study is double-blind, so neither participants nor researchers know who receives revumenib or placebo during the trial. Treatment and assessments will continue with regular monitoring. During the study, participants undergo multiple assessments including evaluation of event-free survival and measurable residual disease complete remission rates over up to 2 years. Additional outcomes like overall survival and response rates are tracked up to 5 years. Safety is monitored by recording treatment-emergent adverse events and changes in patient-reported fatigue. Participants will have various clinical visits and laboratory tests throughout the treatment and follow-up periods to evaluate effectiveness and safety.
1-10 of 12
1